• Best overall response [ Designated as safety issue: No ]
  

• Clinical benefit [ Designated as safety issue: No ]
  
• Time to progression [ Designated as safety issue: No ]
  
• Correlation of F-18 16 alpha-fluoroestradiol uptake with estrogen receptor assays [ Designated as safety issue: No ]
  

OBJECTIVES:

Primary

• Estimate the ability of F-18 16 alpha-fluoroestradiol (FES) positron emission tomography (PET) or FES-PET/CT scan to predict overall response (OR) to first-line endocrine therapy for metastatic breast cancer.

Secondary

• Evaluate the independent role of [^18F] FES in predicting response and time to progression in patients treated with first-line endocrine therapy for metastatic breast cancer.
• Examine the role of [^18F] FES in predicting OR or clinical benefit, in concert with tissue assay of levels of ER mRNA measured using quantitative PCR, and semi-quantitative interpretation of estrogen receptor (ER), progesterone receptor, androgen receptor, and human epidermal growth factor-2 (HER2), in addition to serial measures of hormone levels in plasma.
• Evaluate the relationships among [^18F] FES, semi-quantitative ER from IHC, and ER mRNA as measured by quantitative PCR.
• Document the safety profile of [^18F] FES PET in newly diagnosed patients with metastatic breast cancer.
• Evaluate [^18F] FES standard uptake value (SUV) ≤ 1.5 as the optimal cutpoint for predicting OR to first-line endocrine therapy for metastatic breast cancer.
• Estimate the rate of [^18F] FES SUV < 1.5 in newly diagnosed metastatic breast cancer patients planning a course of endocrine therapy.

OUTLINE: Patients undergo clinical fludeoxyglucose F 18 (FDG)-positron emission tomography (PET) or FDG-PET/CT scanning. Within 14 days later, patients undergo F-18 16 alpha-fluoroestradiol ([^18F] FES) PET scanning prior to initiation of hormone therapy.

Patients receive hormone therapy per standard therapy guideline 14 days after PET scans.

After completion of hormone therapy, patients are followed periodically for 6 months.

DISEASE CHARACTERISTICS:

• Pathologically confirmed diagnosis of metastatic breast cancer with biopsy of at least one site of disease

  • Stage IV disease (M1)

• Disease must be measurable in at least one non-liver and non-bone site (by RECIST criteria) and imageable on fludeoxyglucose F 18 PET scan

  • Elevated tumor markers alone are insufficient
  • No evaluable disease only (e.g., osseous sites of disease only)

• Tumor HER2/neu expression must be determined prior to study enrollment

  • Assessment may be by fluorescence in situ hybridization (FISH) assay or by IHC
  • FISH must be performed if determination is intermediate by IHC

• Patients must be planning a course of endocrine therapy with one of the following:

  • Tamoxifen
  • Ovarian suppression using an aromatase inhibitor
  • Fulvestrant with ovarian suppression in pre-menopausal patients or fulvestrant alone
• No HER2/neu positive disease and not planning to undergo HER2-directed therapy (trastuzumab or lapatanib)
• No visceral crisis characterized by rapidly progressive hepatic or lymphangitic lung metastases

• Positive for estrogen receptor (ER) and may or may not be positive for progesterone receptor by IHC in the primary tumor and/or metastatic site

  • Pathology report for assay of ER will be reviewed by one of the investigators prior to enrollment, the study pathologist will review the pathology report if necessary for determination of study eligibility

PATIENT CHARACTERISTICS:

• Known menopausal status

  • Postmenopausal is defined as:

    • A prior documented bilateral oophorectomy
    • A history of at least 12 months without spontaneous menstrual bleeding
    • Age 60 or older with a prior hysterectomy without oophorectomy
    • Age less than 60 with a prior hysterectomy without oophorectomy (or in whom the status of the ovaries is unknown), with a documented FSH level demonstrating confirmatory elevation in the postmenopausal range for the lab
  • Premenopausal patients must have a baseline FSH, and estradiol levels to determine menopausal status
• ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%
• Life expectancy >16 weeks
• ANC ≥ 1,000/mm³
• Platelet count ≥ 50,000/mm³
• Hemoglobin normal
• Creatinine ≤ 1.5 times upper limit of normal (ULN) and estimated creatinine clearance > 50 mL/min
• Bilirubin ≤ 1.5 times ULN
• AST and ALT ≤ 1.5 times ULN
• Alkaline phosphatase ≤ 2.5 times ULN
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No history of uncontrolled seizures, central nervous system disorders, or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent
• No other life-threatening illness (e.g., serious, uncontrolled concurrent infection or clinically significant cardiac disease - congestive heart failure, symptomatic coronary artery disease, cardiac arrhythmia not well controlled with medication)
• Not medically unstable as judged by the patient's physician
• No psychological, familial, sociological, or geographical conditions which do not permit compliance with the study protocol
• No known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals (patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigator's discretion)
• Body weight ≤ 400 lbs
• No uncontrolled diabetes mellitus, defined as fasting glucose > 200 mg/dL
• No adult patients who require monitored anesthesia for PET scanning
• No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for 5 years

PRIOR CONCURRENT THERAPY:

• Meets 1 of the following criteria:

  • No prior endocrine therapy for metastatic disease
  • Off adjuvant endocrine therapy for > 6 months
  • Single adjuvant endocrine therapy duration of > 2 years at the time of first recurrence and plan to change to alternate endocrine therapy
• More than 6-8 weeks since prior tamoxifen
• Prior chemotherapy regimens in the adjuvant or neoadjuvant setting are allowed
• Prior adjuvant luteinizing hormone-releasing hormone analog allowed
• No other concurrent investigational or commercial agents or therapies for the treatment of this disease